Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Anaptys picks up rival to Biogen autoimmune asset from Centessa
Anaptys is picking up a challenger to Biogen's late-phase lupus candidate, paying Centessa $7 million upfront for rights to a preclinical prospect.
Nick Paul Taylor
Nov 28, 2023 6:30am
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Oct 26, 2023 8:51am
'Harvest time' arrives for Alzheimer's thanks to new treatments
Oct 16, 2023 6:00am
New Biogen research chief aims to add biotech hustle to pharma
Oct 10, 2023 10:50am
Madrigal COO departs days after new CEO starts—Chutes & Ladders
Sep 29, 2023 9:30am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
